Joe Biden's FDA put abortion pills in the mail with no doctor ever laying eyes on the mother.
Pro-life families were promised a federal safety review that would finally slam that mailbox shut.
In a court filing, the FDA told a federal judge exactly how long that mailbox stays open.
FDA Delays Abortion Pill Safety Review Until March 2027
In a court filing on October 7, 2026, the Food and Drug Administration said it will not finish its safety review of mifepristone until March 2027.
No new restrictions before then.
Not one.
The agency expects to wrap up a safety study by mid-December, then deliver a report on its findings no later than March.
Only then will the FDA even decide whether the rules for prescribing and shipping the drug need to change.
That is five more months of abortion pills moving through the U.S. mail into states that ban abortion.
Five more months of babies lost and mothers sent home to bleed alone.
The filing exists because Louisiana forced it.
Attorney General Liz Murrill sued the FDA in October 2025, arguing mail-order pills gut the state's pro-life law.
"Out-of-state abortion drug peddlers are violating the criminal laws of Louisiana," Murrill said.
Standing beside her in that lawsuit is Rosalie Markezich, a Louisiana woman who never wanted an abortion.
In October 2023, her then-boyfriend had abortion pills shipped to her from a California doctor, and she took them out of fear.
Her lawyers at Alliance Defending Freedom say she was cornered into an abortion she never chose, with no doctor in sight.
That is what mail-order abortion looks like from the inside.
A federal judge in that case ordered the FDA to show its work.
The October 7 filing was the first real look at the review Health Secretary Robert F. Kennedy Jr. ordered in 2025.
What the FDA described is a "statistical data mining method" that combs its injury-reporting database for safety problems nobody has flagged yet.
Americans United for Life has called that database flawed, and for good reason.
Since 2016, the FDA has required abortion pill prescribers to report only deaths – not the hemorrhages, infections, and emergency surgeries that follow.
Mifepristone Side Effects Hit One in Nine Women in Insurance Claims Study
The FDA label and the abortion industry put serious complications from mifepristone at under half a percent.
The Ethics and Public Policy Center looked at what happened to real women instead.
Its review of insurance claims covering 865,727 mifepristone abortions found 10.93 percent of women suffered sepsis, infection, hemorrhaging, or another serious or life-threatening event.
That is roughly one in every nine women.
Data filed in State of Louisiana v. FDA puts the serious adverse-event rate at 10.15 percent before Biden's FDA dropped the in-person doctor visit and 11.5 percent after.
The same filing found a serious adverse event was 1.53 to 2.33 times as likely when the pill was dispensed remotely.
The mailbox is making it worse.
This drug came to market in 2000 with real guardrails, including in-person doctor visits.
Obama's FDA stripped most of them away in 2016, letting non-doctors prescribe and cutting required visits to one.
Biden's FDA tossed the last in-person visit during COVID in 2021, then made that permanent in 2023.
Louisiana v. FDA Puts Mail Order Abortion Pills On Trial
John Mize, chief executive of Americans United for Life, pointed out the review was announced in September 2025.
"Since then, we have seen no public evidence this review has actually begun," Mize said.
Students for Life of America President Kristan Hawkins said the status report falls short.
"FDA needs a reality check, and fast," Hawkins said.
Pro-life leaders point to a faster fix on the table – the FDA could settle with Louisiana and restore the in-person safeguard immediately.
That matters because the courts have stalled.
In May 2026, the 5th Circuit ordered the in-person requirement restored nationwide, only for Justice Samuel Alito to pause that order while the Supreme Court weighs the case.
RFK Jr. Can Restore In-Person Abortion Pill Dispensing Without Waiting for March
The bureaucrats who loosened these rules never needed 18 months to put more pills in more mailboxes.
They moved at lightning speed when the goal was easier abortions.
Now that the goal is protecting women like Rosalie Markezich, the same agency wants a database search and another winter.
One in nine women hurt is not a mystery waiting for a computer to dig it up.
It is a known one, sitting in hundreds of thousands of insurance records and Louisiana's court filings.
Robert F. Kennedy Jr. ordered this review, and he can push the FDA to settle with Louisiana and put a doctor back in the room before the December study is even finished.
Sources:
- Steven Ertelt, "FDA Postpones Review of Dangerous Abortion Pill to March 2027," LifeNews, October 8, 2026.
- Steven Ertelt, "Pro-Life Groups Demand FDA Admit Massive Problems With Abortion Pills," LifeNews, October 6, 2026.
- Ethics and Public Policy Center, "Largest-Ever Study of Abortion Pill Reveals Shocking Number of Adverse Events," Ethics and Public Policy Center, April 28, 2025.
- Alliance Defending Freedom, "Louisiana, ADF Challenge Biden-Era Abortion-by-Mail Scheme in Pro-Life States," Alliance Defending Freedom, October 14, 2025.
- Students for Life of America, "FDA Chemical Abortion Pill Status Report NOT ENOUGH," Students for Life of America, October 7, 2026.

